"EXPRESS MAIL" MAILING LABEL NUMBER EL808219712US

Attorney Docket No. P31831C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Stephen A. Smith	August 13, 2001
Serial No.:	Not Assigned	Group Art Unit No.: Not Assigned
Filed:	Herewith	Examiner: Not Assigned
For:	TREATMENT OF DIABETES WITH ROSIGLITAZONE AND INSULIN	

PRELIMINARY AMENDMENT

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

In the specification:

Kindly add the Abstract enclosed herewith on a separate sheet, at the end.

In the claims:

Please delete claim 12.

Please amend claims 1, 3-11 and 13 as follows:

1. (Amended) A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I) and insulin, to a mammal in need thereof.

3. (Amended) A method according to claim 2, which comprises the administration of 2 to 12 mg of Compound (I).

4. (Amended) A method according to claim 3, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).

5. (Amended) A method according to claim 4, which comprises the administration of 2 to 4mg of Compound (I).

6. (Amended) A method according to claim 4, which comprises the administration of 4 to 8mg of Compound (I).

7. (Amended) A method according to claim 4, which comprises the administration of 8 to 12 mg of Compound (I).

8. (Amended) A method according to claim 5, which comprises the administration of 2 mg of Compound (I).

9. (Amended) A method according to claim 5, which comprises the administration of 4 mg of Compound (I).

10. (Amended) A method according to claim 6, which comprises the administration of 8 mg of Compound (I).

11. (Amended) A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I), insulin and a pharmaceutically acceptable carrier therefor.

13. (Amended) A composition according to claim 11, which comprises up to 12 mg or 2 to 12 mg of Compound (I).

REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Applicants have amended the claims to put them in conformity with the U.S. practice.

No new matter has been introduced.

Respectfully submitted,



Yuriy P. Stercho, Ph.D.
Attorney for Applicants
Registration No. 33,797

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5018
Facsimile (610) 270-5073

n\yps\response\P31831C1\preamd.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

An Abstract of the Invention has been added.

In the claims:

1. (Amended) A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound [(]I) and insulin, to a mammal in need thereof.

3. (Amended) A method according to [claim 1or] claim 2, which comprises the administration of 2 to 12 mg of Compound (I).

4. (Amended) A method according to [any one of] claim[s 1 to] 3, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).

5. (Amended) A method according to [any one of] claim[s 1 to 3] **4**, which comprises the administration of 2 to 4mg of Compound (I).

6. (Amended) A method according to [any one of] claim[s 1 to 3] **4**, which comprises the administration of 4 to 8mg of Compound (I).

7. (Amended) A method according to [any one of] claim[s 1 to 3] **4**, which comprises the administration of 8 to 12 mg of Compound (I).

8. (Amended) A method according to [any one of] claim[s 1 to 3] **5**, which comprises the administration of 2 mg of Compound (I).

9. (Amended) A method according to [any one of] claim[s 1 to 3] **5**, which comprises the administration of 4 mg of Compound (I).

10. (Amended) A method according to [any one of] claim[s 1 to 3] **6**, which comprises the administration of 8 mg of Compound (I).

11. (Amended) A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound [(]I), insulin and a pharmaceutically acceptable carrier therefor.

13. (Amended) A composition according to claim 11 [or claim 12], which comprises up to 12 mg or 2 to 12 mg of Compound (I).